Abstract
Radiation therapy （RT） for early-stage glottic cancer （Stage Ⅰ, Ⅱ） achieves high local control and voice preservation rates. While standard fractionated RT （2Gy/fr） is still widely used, hypofractionated RT, which completes treatment in a shorter period, is gaining attention. This study retrospectively examined the efficacy and safety of a 52.5Gy/16fr （3.28Gy/fr） hypofractionated regimen performed at our institution. Nineteen patients who underwent a 16 fraction hypofractionated regimen for early-stage laryngeal cancer between 2011 and 2024 were included. The five-year local control and laryngeal preservation rates were both 100％, with overall survival rates of 100％ at 1 year, 81％ at 3 years, and 56％ at 5 years. Progression-free survival rates were 95％ at 1 year, 77％ at 3 years, and 53％ at 5 years. Acute adverse events included dermatitis （Grade 1/2/3＝15/4/0 patients） and mucositis （Grade 1/2/3＝4/14/1 patients）. Late adverse effects included 2 cases of Grade 1 dysphagia, with no other late adverse events observed. These findings suggest that the 52.5Gy/16 fraction hypofractionated RT is a safe and effective treatment option for patients who require a shorter treatment period.
